| Alithea Genomics–Novalis Biotech: investment, 202303 seed financing round extension totalling CHF2.8m incl existing + lead investor Novalis Biotech AF |
2024-03-14 |
| Tubulis–Fund+: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Fund+ |
2024-03-14 |
| BioLizard–MC Services: public relations, 202401 service existent by MC Services |
2024-01-23 |
| Obulytix–OBN: investor conference, 202401 supply service Obulytix presents at BioSeed 2024 London |
2024-01-22 |
| IBA (BE)–Univ Kansas: proton therapy, 202312– colllab research using ConformalFLASH technology on ProteusONE system with KUMC |
2023-12-05 |
| Bioxodes–SEVERAL: investment, 202311 financing round Series A €8.6m from existing investors |
2023-11-21 |
| Bioxodes–Wallonia (govt): grant, 202311 non-dilutive funding €3.4m from Walloon region |
2023-11-21 |
| Agomab Therapeutics–Canaan Partners: investment, 202310 financing round Series C totalling $100m incl new + co-investor Canaan |
2023-10-10 |
| Agomab Therapeutics–EQT: investment, 202310 financing round Series C totalling $100m incl new + co-investor EQT Life Sciences |
2023-10-10 |
| Agomab Therapeutics–Fidelity: investment, 202310 financing round Series C totalling $100m incl lead investor Fidelity Mgt and Research |
2023-10-10 |
| Agomab Therapeutics–KKR: investment, 202310 financing round Series C totalling $100m incl new + co-investor Dawn Biopharma |
2023-10-10 |
| Agomab Therapeutics–OTHER: investment, 202310 financing round Series C totalling $100m incl existing investors |
2023-10-10 |
| Agomab Therapeutics–SEVERAL: investment, 202310 financing round Series C $100m (€94.9m) led by Fidelity Mgt and Research Company |
2023-10-10 |
| Aboleris Pharma–SEVERAL: investment, 202309 financing round Series A €23.7m led by Caixa Capital Risc + co-led by Sound Bioventures |
2023-09-18 |
| Broken String Biosciences–Heran Partners: investment, 202309 financing round Series A totalling $15m incl new + co-investor Heran Partners |
2023-09-18 |
| Aphea.Bio–SEVERAL: investment, 202307 financing round Series C €70m led by Innovation Industries |
2023-07-11 |
| Rewind Therapeutics–Golgi Neurosciences: investment, 202307 existent investment at time of spin-off of Golgi Neurosciences from Axxam |
2023-07-05 |
| Innovative Health Initiative–EU (govt): grant, 202306– funding €24m for IMAGIO project from IHI |
2023-06-20 |
| Innovative Health Initiative–Philips: targeted cancer therapy, 202306– Philips is coordinating partner ot the IMAGIO project of IHI |
2023-06-20 |
| Innovative Health Initiative–Thermosome: targeted cancer therapy, 202306– Thermosome is partner in IMAGIO project of IHI |
2023-06-20 |
| Santero Therapeutics–Belgium (govt): investment, 202306 financing round Series A totalling €8m incl co-investor SFPIM |
2023-06-07 |
| Santero Therapeutics–Newton Biocapital: investment, 202306 financing round Series A totalling €8m incl lead investor Newton Biocapital |
2023-06-07 |
| Santero Therapeutics–OTHER: investment, 202306 financing round Series A totalling €8m incl a group of business angels led by Pierre Drion |
2023-06-07 |
| Santero Therapeutics–Sambrinvest: investment, 202306 financing round Series A totalling €8m incl co-investor Sambrinvest |
2023-06-07 |
| Santero Therapeutics–SEVERAL: investment, 202306 financing round Series A €8m led by Newton Biocapital |
2023-06-07 |
| Santero Therapeutics–Wallonia (govt): investment, 202306 financing round Series A totalling €8m incl co-investor WE Life Sciences |
2023-06-07 |
| Mithra Pharmaceuticals–BioConfidant: public relations, 202305 service existent by Cohesion Bureau |
2023-05-29 |
| Michor Consulting–QbD Group: investment, 202305 acquisition of Michor Consulting by QbD Group |
2023-05-25 |
| Turnstone Communications–QbD Group: investment, 202305 acquisition of Turnstone Communications by QbD Group |
2023-05-25 |
| Dualyx–Andera Partners: investment, 202305 financing round Series A totalling €40m incl new + co-lead investor Andera Partners |
2023-05-15 |
| Dualyx–BioGeneration Ventures: investment, 202305 financing round Series A totalling €40m incl existing + co-investor BGV |
2023-05-15 |
| Dualyx–Consilium: public relations, 202305 service existent by Consilium Strategic Communications |
2023-05-15 |
| Dualyx–Flanders (govt): investment, 202305 financing round Series A totalling €40m incl existing + co-investor PMV |
2023-05-15 |
| Dualyx–Forbion: investment, 202305 financing round Series A totalling €40m incl new + co-lead investor Forbion |
2023-05-15 |
| Dualyx–Fountain Healthcare Partners: investment, 202305 financing round Series A totalling €40m incl new + co-lead investor Fountain HP |
2023-05-15 |
| Dualyx–High-Tech Gründerfonds: investment, 202305 financing round Series A totalling €40m incl existing + co-investor HTGF |
2023-05-15 |
| Dualyx–SEVERAL: investment, 202305 financing round Series A €40m co-led by Fountain Heathcare Partners + Forbion + Andera Partners |
2023-05-15 |
| Dualyx–Univ Leuven: investment, 202305 financing round Series A totalling €40m incl existing + co-investor GFF |
2023-05-15 |
| Dualyx–V-Bio Ventures: investment, 202305 financing round Series A totalling €40m incl existing + co-investor V-Bio Ventures |
2023-05-15 |
| Dualyx–VIB: investment, 202305 financing round Series A totalling €40m incl existing + co-investor VIB |
2023-05-15 |
| UCB–Ariceum Therapeutics: targeted radiopharmaceuticals, 202305– collab strategic r+d for TRTs for solid tumours + immune-related diseasees |
2023-05-11 |
| Biocartis–HiloProbe: molecular diagnostics, 202305– collab distribution of ColoNode by Biocartis in Europe + possible developm for Idylla platform |
2023-05-09 |
| Anavo Therapeutics–Bioqube Ventures: investment, 202305 seed financing round extenstion totalling €8.5m incl existing investor Bioqube Ventures |
2023-05-02 |
| Complement Therapeutics–Gimv: investment, 202304 financing round Series A totalling €72m incl new + lead investor Gimv |
2023-04-17 |
| Biocartis–APIS Assay Technologies: molecular diagnostics, 202304– collab developm + commerc APIS Breast Cancer Subtyping assay on Idylla platform |
2023-04-04 |
| Galapagos–Novalix: drug discovery services, 202303– collab 5 years in connection with acquisition of Galapagos Romainville by Novalix |
2023-03-30 |
| Mediar Therapeutics–Gimv: investment, 202303c financing round Series A totalling $85m incl co-investor Gimv |
2023-03-15 |
| Galapagos–Iktos: AI-based drug discovery, 202303 collab existent or prior to 3/23 |
2023-03-09 |
| UCB–Cancer Research UK: antibody cancer drugs, 202303– collab clinical development of UCB6114 + UCB4594 |
2023-03-09 |
| UCB–Iktos: AI-based drug discovery, 202303 collab existent or prior to 3/23 |
2023-03-09 |
| Confo Therapeutics–Trophic Communications: public relations, 202303 service existent by Trophic |
2023-03-02 |
| Lilly–Confo Therapeutics: AT2R inhibitor, 202303– license ww excl for CFTX-1554 + backup compounds $40m upfront + $590m milestones/program + royalties |
2023-03-02 |
| Paleo–DSM: investment, 202302 financing round Series A totalling €12m incl co-lead investor DSM Venturing |
2023-02-22 |
| Paleo–Planet A: investment, 202302 financing round Series A totalling €12m incl co-lead investor Planet A Ventures |
2023-02-22 |
| Paleo–SEVERAL: investment, 202302 financing round Series A €12m led by DSM Venturing + Planet A Ventures |
2023-02-22 |
| Rarity Bioscience–Novalis Biotech: investment, 202302 investment €0.5m by Novalis BIotech as extension of seed round now totalling €3m |
2023-02-06 |
| DeuterOncology–Andrew Lloyd Associates: public relations, 202301 service existent by ALA |
2023-01-19 |
| DeuterOncology–Investsud: investment, 202301 financing round Series A toatlling €5.65m incl new investor Investsud Tech |
2023-01-19 |
| DeuterOncology–Newton Biocapital: investment, 202301 financing round Series A toatlling €5.65m incl existing investor Newton Biocapital |
2023-01-19 |
| DeuterOncology–Noshaq: investment, 202301 financing round Series A toatlling €5.65m incl new investor Noshaq |
2023-01-19 |
| DeuterOncology–SEVERAL: investment, 202301 financing round Series A €5.65m with Newton Biocapital + Noshaq + Investsud Tech |
2023-01-19 |
| Vésale Bioscience–Andrew Lloyd Associates: public relations, 202301 service existent by ALA |
2023-01-17 |
| Vésale Bioscience–EU (govt): grant, 202301 EIC Accelerator grant €1.8m for develpment of PhageDiag phagogramme |
2023-01-17 |
| S-Biomedic–Beiersdorf: investment, 202212 acquisition €na of majority share in S-Biomedic NV by Beiersdorf AG |
2022-12-16 |
| ExeVir Bio–EU (govt): credit, 202212– venture debt financing €25m from EIB for develoment of nanobody Covid-19 therapy |
2022-12-14 |
| MyCellHub–SEVERAL: investment, 202212 financing round €2m with Gemma Frisius Fund + Noshaq + The Factory Fund + LRM |
2022-12-08 |
| Xpress Biologics–Polyplus-transfection: investment, 202212 acquisition of Xpress Biologics by Polyplus from ArchiMed et al |
2022-12-07 |
| VIB–Resolve Biosciences: Molecular Cartography technology, 202210 supply to VIB existent as one of first customers |
2022-10-24 |
| Enhanc3D Genomics–Bioqube Ventures: investment, 202210 financing round Series A totalling £10m incl existing + co-investor Bioqube Ventures |
2022-10-20 |
| Orionis Biosciences–SEVERAL: investment, 202210 financing round $55m with Cormorant AM + Novartis et al |
2022-10-19 |
| Univercells–SEVERAL: investment, 202210 financing round Series D 1st closing €44m with SFPI-FPIM + SRIW et al |
2022-10-19 |
| Mablink Bioscience–Fournier-Majoie Foundation: investment, 202210 financing round Series A totalling €31m incl existing + co-investor Fondation FM |
2022-10-14 |
| Sibylla Biotech–V-Bio Ventures: investment, 202210 financing round Series A totalling €23m incl lead investor V-Bio Ventures |
2022-10-04 |
| Tridek-One–Bioqube Ventures: investment, 202209 2nd financing round totalling €16m incl new + co-investor Bioqube Ventures |
2022-09-15 |
| Standing Ovation–Astanor Ventures: investment, 202209 financing round Series A totalling €12m incl lead investor Astanor Ventures |
2022-09-14 |
| eTheRNA–China Grand Pharma: investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor Grand Pharma |
2022-08-23 |
| eTheRNA–EQT: investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor EQT Life Sciences (formerly LSP) |
2022-08-23 |
| eTheRNA–Flanders (govt): investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor PMV |
2022-08-23 |
| eTheRNA–Fund+: investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor Fund+ |
2022-08-23 |
| eTheRNA–Novalis LifeSciences: investment, 202208 financing round Series B2 totalling €39m incl existing + lead investor Novalis LifeSciences LLC |
2022-08-23 |
| eTheRNA–Omega Funds: investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor Omega Fund |
2022-08-23 |
| eTheRNA–PERSON: investment, 202208 financing round Series B2 totalling €39m incl new + co-investor Kenneth Chien |
2022-08-23 |
| eTheRNA–SEVERAL: investment, 202208 financing round Series B2 €39m led by existing investor Novalis LifeSciences LLC |
2022-08-23 |
| Agomab Therapeutics–Asabys Partners: investment, 202207 financing round Series B extension totalling $40.5m incl new + co-investor Asabys Partners |
2022-07-13 |
| Agomab Therapeutics–OTHER: investment, 202207 financing round Series B extension totalling $40.5m incl existing-investors |
2022-07-13 |
| Agomab Therapeutics–Pfizer: investment, 202207 financing round Series B extension totalling $40.5m incl new + lead investor Pfizer Breakthrough GI |
2022-07-13 |
| Agomab Therapeutics–SEVERAL: investment, 202207 financing round Series B extension $40.5m led by Pfizer bringing total Series B to $114m |
2022-07-13 |
| Agomab Therapeutics–Walleye Capital: investment, 202207 financing round Series B extension totalling $40.5m incl new + co-investor Walleye Capital |
2022-07-13 |
| Abound Bio–Galapagos: investment, 202206 acquisition $14m in cash of AboundBio by Galapagos |
2022-06-21 |
| CellPoint–Galapagos: investment, 202206 acquisition in cash €125m upfront + €100m milestones of CellPoint by Galapagos |
2022-06-21 |
| JnJ–Evotec: drug discovery services, 202206– collab discover novel mode of action drugs using TargetAlloMod platforms for Janssen Pharmaceutica |
2022-06-14 |
| ImCheck Therapeutics–Gimv: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Gimv |
2022-06-13 |
| ImmunOs Therapeutics–Gimv: investment, 202206 financing round Series B totalling $74m incl new + co-lead investor Gimv |
2022-06-07 |
| Vizgen–Sofina: investment, 202206 financing round Series C totalling $85.2m incl co-investor Sofina |
2022-06-03 |
| Minoryx–Fund+: investment, 202205 financing round Series C incl existing + co-investor Fund+ |
2022-05-31 |
| CureVac–myNEO: drug target discovery, 202205– collab research + option agreem antigen targets for mRNA cancer vaccines |
2022-05-25 |
| Alithea Genomics–Novalis Biotech: investment, 202205 seed financing round totalling CHF1m incl lead investor Novalis Biotech Acceleration Fund |
2022-05-24 |
| Domain Therapeutics–Theodorus: investment, 202205 financing round Series A totalling €39m incl co-investor Theodorus |
2022-05-10 |
| Tubulis–Fund+: investment, 202205 financing round Series B totalling €60m incl new + co-investor Fund+ |
2022-05-03 |
| Monkeys not Donkeys–Quality by Design (QbD): investment, 202204 acquisition of MnD by QbD |
2022-04-13 |
![[LSBNL] Life-Sciences-Benelux.com - The Benelux Life Sciences Web Portal](/images/basics/lsbnl-life-sciences-benelux-portal-logo.svg){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
